Clinical trial
A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
NCT06461286 is registered in ClinicalTrials.gov with PYC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
- Lead sponsor
- PYC Therapeutics
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 31, 2024
- Completion date
- November 30, 2029
- Enrollment
- 18 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
autosomal dominant optic atrophy, hereditary optic atrophies, kjer optic atrophy, opa1 gene mutation